Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Place-controlled WILLOW Trial

RECOMMENDED

Further Publications

Dual αvβ6 and αvβ1 Inhibition Over 12 Weeks Reduces Active Type 1 Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Am J Respir Crit Care Med

Montesi SB, Cosgrove GP, Turner SM, Zhou IY, Efthimiou N, Susnjar A, Catana C, Fromson C, Clark A, Decaris M, Barnes CN, Lefebvre ÉA, Caravan P

doi: 10.1164/rccm.202410-1934OC

COMMENTED

Asthma

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, González-Barcala FJ, Bourdin A, Ostrovskyy M, Staevska M, Chou PC, Duca L, Pereira AM, Fogarty C, Nadama R, Zhang M, Rodrigues A, Soler X, Sacks HJ, Deniz Y, Rowe PJ, de Prado Gómez L, Jacob-Nara JA

doi: 10.1016/S2213-2600(24)00362-X

COMMENTED

Bronchi

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

N Engl J Med

Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML, ASPEN Investigators

doi: 10.1056/NEJMoa2411664

COMMENTED

Cough

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet

Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, Maspero J, Fujieda S, Zhang L, Sousa AR, Woods SJ, Davis AM, Schalkwijk S, Edwards D, Ranganathan P, Follows R, Marshall C, Han JK, ANCHOR-1 and ANCHOR-2 trial investigators

doi: 10.1016/S0140-6736(25)00197-7

COMMENTED

Bronchi

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

Lancet Respir Med

Haworth CS, Shteinberg M, Winthrop K, Barker A, Blasi F, Dimakou K, Morgan LC, O'Donnell AE, Ringshausen FC, Sibila O, Thomson RM, Carroll KJ, Pontenani F, Castellani P, Chalmers JD, PROMIS trial investigators

doi: 10.1016/S2213-2600(24)00225-X

COMMENTED

COPD

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB

doi: 10.1016/S2213-2600(24)00409-0

RECOMMENDED

Pulmonary Hypertension

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M

doi: 10.1164/rccm.202409-1698OC

RECOMMENDED

Cough

Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Birring SS, Cardozo L, Dmochowski R, Dicpinigaitis P, Afzal A, La Rosa C, Lu S, Nguyen AM, Yao R, Reyfman PA

doi: 10.1016/S2213-2600(24)00222-4

RECOMMENDED

COPD

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Higginson IJ, Brown ST, Oluyase AO, May P, Maddocks M, Costantini M, Bajwah S, Normand C, Bausewein C, Simon ST, Ryan K, Currow DC, Johnson MJ, Hart SP, Mather H, Krajnik M, Tanzi S, Ghirotto L, Bolton CE, Janowiak P, Turola E, Jolley CJ, Murden G, Wilcock A, Farsides B, Brown JM, BETTER-B consortium

doi: 10.1016/S2213-2600(24)00187-5

Related content

Dual αvβ6 and αvβ1 Inhibition Over 12 Weeks Reduces Active Type 1 Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial